Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Breast Cancer Clinical Trials in Pittsburgh | 472 Studies

Clinical Trials Breast CancerPittsburgh

Breast Cancer Clinical Trials in Pittsburgh

Find 472 clinical trials for breast cancer near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 301-320 of 472 trials

Active not recruitingA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesTransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.NCT05081609·Los Angeles, California and 67 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in…NCT07114601·Duarte, California and 32 others

RecruitingSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerThe primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2…NCT06380751·Gilbert, Arizona and 305 others

Active not recruitingStudy of INCB123667 in Subjects With Advanced Solid TumorsThis is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when…NCT05238922·Duarte, California and 40 others

CompletedA Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingThis is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of…NCT01808573·Chandler, Arizona and 251 others

Active not recruitingOlaparib In Metastatic Breast CancerThis research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast.NCT03344965·Birmingham, Alabama and 19 others

CompletedA Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerThis study is being done for the following reasons: * The study has two parts.NCT02236000·Weston, Florida and 14 others

RecruitingTesting the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerThis phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in…NCT03606967·Orange, California and 29 others

RecruitingAdding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerThis phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2…NCT06058377·Birmingham, Alabama and 556 others

CompletedStudy of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearThe primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in…NCT00424983·West Hollywood, California and 6 others

Active not recruitingTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.NCT06590857·Phoenix, Arizona and 30 others

CompletedA Study of PRT1419 in Patients With Advanced Solid TumorsThis is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.NCT04837677·Denver, Colorado and 6 others

CompletedComparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00024102·Birmingham, Alabama and 333 others

Active not recruitingEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerThis phase I trial studies the side effects and best dose of entinostat and nivolumab when given together with ipilimumab in treating patients with solid tumors that have spread…NCT02453620·Duarte, California and 4 others

Active not recruitingMARGetuximab Or Trastuzumab (MARGOT)The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different…NCT04425018·Washington D.C., District of Columbia and 13 others

CompletedA Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerThe primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P…NCT02163694·Gilbert, Arizona and 218 others

TerminatedA Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerThe purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the…NCT02202746·Sedona, Arizona and 32 others

No longer availableExpanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed AppropriateTo provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada…NCT02142868·Bakersfield, California and 54 others

WithdrawnTesting the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsThis phase I/Ib trial studies the side effects and best dose of Hu5F9-G4 (magrolimab) when given in combination with olaparib for the treatment of patients with breast or…NCT05807126·Costa Mesa, California and 4 others

Active not recruitingCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCPhase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer…NCT03997123·Whittier, California and 259 others

PreviousPage 16 of 24Next

Other Conditions in Pittsburgh

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma